Mads Hald Andersen
Clinical Professor
Immunology
Blegdamsvej 3B, 2200 København N
Member of:
PERSONAL INFORMATION
Mads Hald Andersen; Nationality: Danish; Date of birth: 24. September 1972; Married, 3 children
EDUCATION and DEGREES
2016 DMSc (dr.med), thesis-title: “Anti-regulatory T cells”
2006 DScTech (dr.techn), “Regulators of apoptosis: Suitable targets for
immunotherapy of cancer”
2001 PhD, Technical University of Denmark (DTU), thesis-title:”Identification of novel
tumor antigens”
1998 Master of Science in Chemical Engineering, DTU, Dept. of Biochem
POSITIONS ACADEMIA
2015 - Professor, Copenhagen University
2006 - Vice-Director, co-Founder Center for Cancer Immunotherapy (CCIT), Dept. of
Hematology, University Hospital Herlev, Denmark
2009-2014 Professor (honorary), Technical University of Denmark, Dept. of Systems Biology
2001 - 2006 Senior Scientist, Tumor Immunology Group, Danish Cancer Society, Copenhagen,
Denmark
2001 Research Fellow, Department of Dermatology, School of Medicine, Würzburg
University Hospital, Germany and Department of Tumor Cell Biology, Danish
Cancer Society, Copenhagen, Denmark
1998 - 2001 PhD-student, Department of Tumor Cell Biology, Danish Cancer
Society. PhD-stipend from Technical University of Denmark
POSITIONS INDUSTRI
2015- Board member, Founder, IO Biotech, Copenhagen
2008 Founder, RhoVac, Hørsholm
2003 - 2006 Chief Executive Officer, Founder, Survac ApS, Hellerup,
PUBLICATIONS
I am author/co-author of 169 accepted publications in international peer reviewed journals. In addition, I am author/co-author on 6 publications, which are submitted for publication. I am in addition author of 9 publications in Danish journals as well as co-author of 5 peer reviewed book chapters. I am author/co-author of 18 patents/patent applications
FELLOWSHIPS AND AWARDS
2012; The Lundbeck Foundation research prize for young researchers under the age of 40. The prize
is a recognition of a particularly promising scientist under the age of 40 who has conducted
outstanding research in biomedicine or the natural sciences. 2009; Honorary Professor, Technical
University of Denmark. 2007; The Hallas-Møller stipend from the Novo Nordisk foundation. 2006;
the Danish Cancer Society Junior Research Award for outstanding efforts in the cancer research
conducted by a scientist under 40. In addition, a long list of stipends from different foundations as
well as several High Impact Awards from Herlev Hospital (honors Prize for outstanding research).
TEACHING AND SUPERVISOR ACTIVITIES
Lecturing since 2002 at the Technical Univeristy of Denmark at the course “Immunology” and since 2010 the course “Development and Production of Vaccines”. Co-organizing the only PhD-course in Denmark in “Tumor Immunology” at the Graduate School of Immunology. Lecturing tumor immunology/immunotherapy at the PhD -courses “tumor biology” and “Clinical Cancer Research” at the PhD-school at the University of Copenhagen. Likewise, lecturing at “Clinical Cancer Biology” at the Universities at Aarhus as well as Southern Denmark. Supervising a number of PhD-students (currently 8) as well as Master-degree students (currently 2) both at Copenhagen University and the Technical University of Denmark. Currently, supervisor of 2 Post docs.
COMMISSIONS
2015- Scientific Adviser, IO Biotech, Copenhagen
2012 - Scientific Advisory Board, Ultimovacs, Oslo, Norway
2012 - 2017 Scientific Advisory, RhoVac, Hørsholm
2006 - 2007 Scientific Adviser, Merck KGaA, Darmstadt, Germany
2004 - 2005 Scientific Adviser, Pharmaxa A/S, Hørsholm
2000 Scientific Adviser, Torsana Oncology Systems A/S, Skodsborg
2012 – Professor evaluations, SDU and DTU
I function as ad hoc reviewer for several international peer reviewed journals, e.g. JCI, JNCI, AACR journals, Gut and Blood. In addition I function as a reviewer for several international research foundations, e.g., the Foundation for Polish Science, UK-ASM Newton, the Christian Doppler Research Association (CDG), Innovation Norway, Research Council of Norway. Special Editor for Seminars in Immunopathology.
RESEARCH HIGHLIGHTS
My research has been focusing on the characterization of the natural immune responses towards malignant cells. I have identified a number of different T-cell antigens including survivin, the Bcl-2 family and RhoC. These are the center for ongoing clinical trials in Europe and USA. Survivin is one of the most commonly used cancer antigens worldwide. Recently, as described in this application, I initiated a brand new research program focusing on antigen-specific immune regulation, e.g. IDO and PD-L1. Recently, we finalized the first ever clinical vaccination trial based on such self-antigens with promising clinical data. My work has received much attention illustrated by the fact that I have been asked to review the field by high ranking journals like Nature Reviews and Journal of the National Cancer Institute. My publications have several times been accompanied by commentaries and articles in both the scientific as well as the popular press.
FUNDING HISTORY
I have previously received direct support from many foundations including: Danish Cancer Society, The Technical University of Denmark, Danish Council for Independent Research, the Capital Region of Denmark The Novo Nordisk Foundation, The Lundbeck foundation, the Danish Cancer Research Foundation, Toyota Foundation, and Herlev Hospital. In addition, I am co-recipient/investigator on several CCIT external grants, including two EU grants.
INVITED SPEAKER
2016-: Roche event (Odense, Denmark); Cellular Therapy (Erlangen, Germany), CANCER IMMUNOTHERAPY & IMMUNOMONITORING, (Ljubljana, Slovenia), the Lankenau Institute for Medical Research, Thomas Jefferson University (Philadelphia, US), Immuno-Oncology (London, UK), JSH 7th International Symposium (Awai, Japan), Cancer vaccines (London, UK), SITC 2016 (Washington USA). I have co-organized several international meetings.
EXAMPLES OF LEADERSHIP IN INDUSTRIAL INNOVATION
I was the founder of SurVac Aps, a company that focused on developing cancer vaccines based on my research. The company was sold to Merck KGaA in 2006. After the acquisition I served as scientific adviser for Merck KGaA until 2007. In 2008, I co-founded another vaccine company, RhoVac. Rhovac was recently introduced at Aktie-torget, Sweden. Recently, I founded yet another comapany IO Biotech ApS with the support from Novo A/S and the Lundbeck Foundation.
ID: 13571778
Most downloads
-
216
downloads
Butyrate and propionate inhibit antigen-specific CD8+ T cell activation by suppressing IL-12 production by antigen-presenting cells
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
170
downloads
Low antigen dose formulated in CAF09 adjuvant Favours a cytotoxic T-cell response following intraperitoneal immunization in Göttingen minipigs
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
169
downloads
Interleukin-26 (IL-26) is a novel anti-microbial peptide produced by T cells in response to staphylococcal enterotoxin
Research output: Contribution to journal › Journal article › Research › peer-review
Published